Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant ...

Germany's foreign intelligence service in 2020 put at 80%-90% the likelihood that the coronavirus behind the COVID-19 ...

Beqvez brings an inauspicious ending to a gene therapy that got its start more than a decade ago in the labs of Spark Therapeutics in Philadelphia. Pfizer's disclosure Friday that it is ending ...

In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis ... companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA.

Pfizer gained as much as 2.6 percent. The lab finding does raise the possibility that this new bat virus could spread from animals to humans, researchers said in a paper published Tuesday in the ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The company’s shares closed yesterday at $26.65.

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...